BCL2 and Alzheimer disease: The results of network pharmacology showed that NBIF treatment of AD involved 62 targets such as SIRT1 and Bcl‐2 (Figure 7A), and various signaling pathways such as neuroactive ligand‐receptor interactions, FoxO and JAK–STAT (Figure 7B).